We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 06. | 장 마감 후 (AMC) | — | — | — | — | — | 예정 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-5.55 | — | — | $1.36M | 보고됨 |
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.27 | — | — | $320K |
Rating & price-target changes
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2025. 11. 19. | Needham | — | 의견 유지 | Hold → Hold | — | Needham: Hold |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
| FY2025 Q1 | 2024. 03. 31. | 시각 미정 | — | $-0.17 | — | — | $230K | 보고됨 |
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Stored first · Google News · Yahoo Finance (English)
Clearside Biomedical Stumbles Through Bankruptcy And Delisting - Finimize
Clearside Biomedical Stumbles Through Bankruptcy And Delisting Finimize
Clearside Biomedical files to delist common stock from Nasdaq after bankruptcy - Investing.com
Clearside Biomedical files to delist common stock from Nasdaq after bankruptcy Investing.com
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - VisionMonday.com
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process VisionMonday.com
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - GlobeNewswire
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process GlobeNewswire
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - Yahoo Finance
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline Yahoo Finance
Clearside Biomedical reports positive topline phase 2b data on CLX-AX for wet AMD - Eyes On Eyecare
Clearside Biomedical reports positive topline phase 2b data on CLX-AX for wet AMD Eyes On Eyecare